HC Wainwright Has Negative Forecast for BCRX FY2025 Earnings

Key Points

• HC Wainwright has lowered its FY2025 EPS estimate for BioCryst Pharmaceuticals, now predicting earnings of $0.06, compared to a previous estimate of $0.07.
• The stock has seen a recent price record with shares up 6.1%, opening at $6.81 on Thursday, despite a market capitalization of $1.43 billion.
• Recent analyst ratings for BioCryst Pharmaceuticals include nine Buy ratings and one Sell rating, with a consensus target price of $19.18.

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) - Stock analysts at HC Wainwright cut their FY2025 EPS estimates for shares of BioCryst Pharmaceuticals in a research note issued to investors on Wednesday, October 15th. HC Wainwright analyst A. Fein now forecasts that the biotechnology company will post earnings per share of $0.06 for the year, down from their prior forecast of $0.07. The consensus estimate for BioCryst Pharmaceuticals' current full-year earnings is ($0.36) per share. HC Wainwright also issued estimates for BioCryst Pharmaceuticals' Q4 2025 earnings at $0.02 EPS and FY2029 earnings at $1.71 EPS.

Several other equities analysts have also recently weighed in on the stock. Royal Bank Of Canada reiterated an "outperform" rating and issued a $13.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Monday, June 30th. Needham & Company LLC increased their price objective on shares of BioCryst Pharmaceuticals from $17.00 to $20.00 and gave the stock a "buy" rating in a research note on Wednesday. JMP Securities increased their price objective on shares of BioCryst Pharmaceuticals from $17.00 to $27.00 and gave the stock a "market outperform" rating in a research note on Wednesday. Zacks Research upgraded shares of BioCryst Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Monday, October 6th. Finally, Wedbush raised their target price on shares of BioCryst Pharmaceuticals from $16.00 to $18.00 and gave the stock an "outperform" rating in a research note on Monday, June 30th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, BioCryst Pharmaceuticals has an average rating of "Moderate Buy" and a consensus target price of $19.18.

BioCryst Pharmaceuticals Stock Up 6.1%

Shares of NASDAQ:BCRX opened at $6.81 on Thursday. The firm's 50 day moving average price is $7.90 and its 200-day moving average price is $8.65. BioCryst Pharmaceuticals has a twelve month low of $6.00 and a twelve month high of $11.31. The stock has a market capitalization of $1.43 billion, a PE ratio of -37.83, a price-to-earnings-growth ratio of 1.28 and a beta of 1.05.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last announced its quarterly earnings results on Monday, August 4th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.03 by $0.12. The company had revenue of $163.35 million for the quarter, compared to analysts' expectations of $149.59 million. The business's revenue was up 49.5% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.06) EPS.

Insider Buying and Selling at BioCryst Pharmaceuticals

In related news, Director Theresa Heggie sold 70,000 shares of the firm's stock in a transaction on Wednesday, August 13th. The shares were sold at an average price of $8.51, for a total value of $595,700.00. Following the completion of the transaction, the director directly owned 65,352 shares of the company's stock, valued at approximately $556,145.52. This trade represents a 51.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 5.10% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of BCRX. GAMMA Investing LLC grew its holdings in shares of BioCryst Pharmaceuticals by 1,161.8% in the first quarter. GAMMA Investing LLC now owns 5,918 shares of the biotechnology company's stock valued at $44,000 after purchasing an additional 5,449 shares in the last quarter. SG Americas Securities LLC grew its holdings in shares of BioCryst Pharmaceuticals by 5.2% in the first quarter. SG Americas Securities LLC now owns 43,496 shares of the biotechnology company's stock valued at $326,000 after purchasing an additional 2,146 shares in the last quarter. Wealth Enhancement Advisory Services LLC grew its holdings in shares of BioCryst Pharmaceuticals by 113.7% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 37,671 shares of the biotechnology company's stock valued at $283,000 after purchasing an additional 20,043 shares in the last quarter. Allspring Global Investments Holdings LLC purchased a new position in shares of BioCryst Pharmaceuticals in the first quarter valued at $79,000. Finally, Cerity Partners LLC boosted its stake in BioCryst Pharmaceuticals by 203.6% during the first quarter. Cerity Partners LLC now owns 36,410 shares of the biotechnology company's stock worth $273,000 after buying an additional 24,418 shares during the period. 85.88% of the stock is owned by hedge funds and other institutional investors.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.